Nadmed brings to market a new type of NAD metabolite measurement technology.
NADMED has raised $3.9M in total funding. The most recent round was Series A. The last funding was announced in August 2024.
NADMED's investors include Nordic Science Investments, Voima Ventures, Business Finland, University of Helsinki, CVX Ventures.
NADMED is headquartered in Helsinki, Finland.
Nadmed brings to market a new type of NAD metabolite measurement technology.
NADMED is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"NADMED — Funding & Investors." VCBacked, August 22, 2024, https://www.vcbacked.co/company/nadmed. Accessed October 29, 2026.
VCBacked. (2024). NADMED — Funding & Investors. Retrieved October 29, 2026, from https://www.vcbacked.co/company/nadmed
{{cite web |title=NADMED — Funding & Investors |url=https://www.vcbacked.co/company/nadmed |website=VCBacked |access-date=October 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated